Extended Data Fig. 7: Effect of garetosmab on flare-up events.

Percent of patients with new flare-up events as reported by a, patient diary and b, investigator AE verbatim term in period 1 (active HO analysis set). Panels C–E describe patients who crossed over from placebo in period 1 to garetosmab in period 2. Percent of patients with new flare-up events as reported by c, patient diary and d, investigator AE verbatim term for patients originally assigned to placebo (mITT analysis set). Total number of new flare-up events as reported by e, patient diary and f, investigator AE verbatim term for patients originally assigned to placebo (mITT analysis set). A new flare-up was defined as a flare-up event starting in the corresponding period. Investigator-defined flare-ups were defined as TEAEs with the verbatim term containing ‘flare’. Nominal P values are not shown for post-hoc analyses, that is, panels A–D. AE, adverse event; HO, heterotopic ossification; mITT, modified intent-to-treat; TEAE, treatment-emergent adverse event.